-+ 0.00%
-+ 0.00%
-+ 0.00%

Vivos Therapeutics FY25 net loss widens to $21.2 million; revenue rises 16% to $17.5 million

PUBT·04/15/2026 20:20:20
Listen to the news
Vivos Therapeutics FY25 net loss widens to $21.2 million; revenue rises 16% to $17.5 million
  • Vivos Therapeutics posted a net loss of $21.2 million for full-year 2025, widening from $11.1 million.
  • Revenue rose 16% to $17.5 million.
  • Operating loss widened to $19.9 million as operating expenses climbed to $30.4 million.
  • Management cited higher sleep testing services and contribution from two Nevada locations of The Sleep Center of Nevada, offset by a wind-down in VIP enrollment revenue.
  • CEO Kirk Huntsman said cost-savings initiatives and a strengthened capital structure support a goal of cash flow positive operations by end of this year.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604151620PRIMZONEFULLFEED9690520) on April 15, 2026, and is solely responsible for the information contained therein.